[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"bronchoalveolar-lavage-bal\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:bronchoalveolar-lavage-bal":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,54],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":33,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":53},"100640851","safety-of-bronchoscopy-in-patients-with-interstitial-lung-disease-100640851",false,"NCT07627594","Safety of Bronchoscopy in Patients With Interstitial Lung Disease","Safety of Bronchoscopy in Patients With Interstitial Lung Disease: A Prospective, Observational, Multicentre, International Study","SaBrILD","Inclusion Criteria:\n\n* Consecutive adult (≥18 years old) patients with suspected or confirmed ILD who need to undergo bronchoscopy as part of their routine clinical practice,\n* Patients able to understand and sign an informed consent\n\nExclusion Criteria:\n\n* Patients who refused the study partecipation;\n* Patients with contraindications to bronchoscopy","ALL","18 Years",{"count":20,"type":21},427,"ESTIMATED","OBSERVATIONAL","Bronchoscopy is an essential technique, routinely used in the differential diagnosis workup of many Interstitial Lung Diseases (ILDs) and in referral centres is a common procedure. Bronchoalveolar lavage (BAL), bronchial and transbronchial biopsies with forceps and cryoprobes, and lymph node sampling with endosonography represent the most used sampling techniques in these patients. However, patients with ILDs refer to medical attention in a wide range of clinical conditions from mild functional impairment, with absent or few respiratory symptoms, to severe lung involvement with low exercise tolerance and\u002For chronic respiratory failure. In these patients, a balance between benefits and risk, i.e. to the safety and diagnostic utility of bronchoscopy should be always carefully evaluated. Moreover, there is a wide variability in adverse events entity and frequency depending by procedures performed during bronchoscopy.\n\nDespite its crucial utility, only few data are available in the literature on the safety of bronchoscopy in patients with ILDs and limited data on the utility and safety of this sampling technique are present in patients with AE-ILDs.\n\nThe primary aim of this study is to assess the overall rate of complications occurring within 24 hours after bronchoscopy. Study rate and type of complications occurring during the endoscopic procedure, within 30 days after bronchoscopy, in patients with AE-ILDs, among fibrotic Vs non-fibrotic ILD, and according to each employed sampling technique will be also recorded.",[25,26,27,28,29,30,31,32],"Interstitial Lung Disease (ILD)","Bronchoscopy","Bronchoalveolar Lavage (BAL)","Acute Exacerbation","Cryobiopsy","Transbronchial Biopsy","Endosonography","Pulmonary Fibrosis",[34,35,36,37,38,39,40],"ILD","BAL","acute exacerbation","cryobiopsy","transbronchial biopsy","interstitial lung disease","pulmonary fibrosis","NOT_YET_RECRUITING","2026-05-29",{"date":44,"type":45},"2026-06-04","ACTUAL",{"date":47,"type":21},"2026-06-01",{"date":49,"type":21},"2028-05-30",{"name":51,"class":52},"University of Milan","OTHER",11,{"id":55,"slug":56,"hasResults":11,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":4,"eligibilityCriteria":60,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":61,"targetDuration":4,"studyType":63,"phases":64,"briefSummary":66,"conditions":67,"keywords":4,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":80},"100578774","phase-2-bal-fluid-biomarkers-in-sarcoma-100578774","NCT06815666","BAL Fluid Biomarkers in Sarcoma","Prospective Study of Biomarkers Derived From Bronchoalveolar Lavage Fluid to Predict Outcomes in Soft-Tissue Sarcomas","Inclusion Criteria:\n\n1. Age ≥ 18 years\n2. Ability to understand and willingness to sign a written informed consent document\n3. Diagnosed with soft tissue sarcoma\n4. Undergoing resection of lung lesion as part of standard care\n\nExclusion Criteria:\n\n1\\. History of another invasive malignancy, except for non-melanoma skin cancer or tumors curatively treated with no evidence of disease for ≥ 2 years",{"count":62,"type":21},70,"INTERVENTIONAL",[65],"PHASE2","This is a single-centre, Phase II, prospective study designed to assess BALF and TA-derived biomarkers in relation to metastatic burden in STS patients. BALF and TA samples will be collected during routine bronchoscopy performed as part of standard care at Toronto General Hospital (TGH). Additionally, tissue samples of lung metastases and adjacent normal lung will be collected and used to correlate the identified biomarkers.",[68,27,69],"Soft Tissue Sarcoma (STS)","Bronchoalveolar Lavage Fluid","RECRUITING","2026-03-03",{"date":73,"type":45},"2026-03-04",{"date":75,"type":45},"2025-01-29",{"date":77,"type":21},"2032-04-01",{"name":79,"class":52},"University Health Network, Toronto",1]